terazosin has been researched along with Urination Disorders in 23 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
Urination Disorders: Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effectiveness of the long-acting alpha(1)-adrenergic receptor blocking agent terazosin compared with placebo on lower urinary tract symptoms and peak urinary flow rate in men with clinical benign prostatic hyperplasia." | 8.81 | Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. ( Boyle, P; Manski, R; Padley, RJ; Robertson, C; Roehrborn, CG, 2001) |
| "The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50." | 6.73 | Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. ( Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF, 2007) |
| "We evaluated the effect of terazosin in the improvement of lower urinary tract symptoms and flank pain in patients with internal ureteral stents." | 5.15 | Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial. ( Esmaeili, S; Farzan, A; Ghodsi, S; Heidari Nejad, S; Mokhtari, G; Shakiba, M, 2011) |
| "To clarify the influence of hypertension on lower urinary tract symptoms (LUTS) we examined the relationship between blood pressure, LUTS, and the effect of terazosin on LUTS in patients with benign prostatic hyperplasia (BPH)." | 5.10 | Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. ( Gakiya, M; Goya, M; Hatano, T; Ikehara, A; Kadekawa, K; Nakayama, T; Nashiro, F; Ogawa, Y; Sugaya, K, 2003) |
| "To evaluate the efficacy and to describe the modalities of use of terazosin hydrochloride dihydrate, prescribed under conditions of routine clinical practice to a vast population of patients with benign prostatic hyperplasia (BPH)." | 5.09 | [Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination]. ( Boumendil, O; Reitz, C; Rossi, D; Serment, G, 2000) |
| "To determine the effectiveness of the long-acting alpha(1)-adrenergic receptor blocking agent terazosin compared with placebo on lower urinary tract symptoms and peak urinary flow rate in men with clinical benign prostatic hyperplasia." | 4.81 | Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. ( Boyle, P; Manski, R; Padley, RJ; Robertson, C; Roehrborn, CG, 2001) |
| "The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50." | 2.73 | Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. ( Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF, 2007) |
| " No unknown adverse reactions were observed in either groups, and the drugs were shown to be highly safe." | 2.70 | [The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy]. ( Fujioka, T; Goto, Y; Isurugi, K; Katoh, T; Numasato, S; Obara, W; Omori, S; Suzuki, Y, 2001) |
| "Treatment with terazosin can reduce patients' episodes of nocturia both subjectively and objectively in some men with LUTS." | 1.33 | alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction. ( Kim, SW; Ku, JH; Paick, JS; Shin, JW; Yang, JH, 2006) |
| "Men participating in the 2001 and 2002 Prostate Cancer Awareness Week screening for prostate cancer were given a self-administered questionnaire." | 1.32 | Herbal and vitamin supplement use in a prostate cancer screening population. ( Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 15 (65.22) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Van Batavia, JP | 1 |
| Combs, AJ | 1 |
| Horowitz, M | 1 |
| Glassberg, KI | 1 |
| Mokhtari, G | 1 |
| Shakiba, M | 1 |
| Ghodsi, S | 1 |
| Farzan, A | 1 |
| Heidari Nejad, S | 1 |
| Esmaeili, S | 1 |
| Merrick, GS | 1 |
| Butler, WM | 1 |
| Wallner, KE | 1 |
| Lief, JH | 1 |
| Galbreath, RW | 1 |
| Johnson, TM | 1 |
| Jones, K | 1 |
| Williford, WO | 1 |
| Kutner, MH | 1 |
| Issa, MM | 1 |
| Lepor, H | 2 |
| Velasco, C | 1 |
| Guarneri, L | 1 |
| Leonardi, A | 1 |
| Testa, R | 1 |
| Sugaya, K | 1 |
| Kadekawa, K | 1 |
| Ikehara, A | 1 |
| Nakayama, T | 1 |
| Gakiya, M | 1 |
| Nashiro, F | 1 |
| Goya, M | 1 |
| Hatano, T | 1 |
| Ogawa, Y | 1 |
| Barqawi, A | 1 |
| Gamito, E | 1 |
| O'Donnell, C | 1 |
| Crawford, ED | 1 |
| Brown, GA | 1 |
| Sussman, DO | 1 |
| Bozlu, M | 1 |
| Ulusoy, E | 1 |
| Cayan, S | 1 |
| Akbay, E | 2 |
| Görür, S | 1 |
| Paick, JS | 2 |
| Ku, JH | 3 |
| Shin, JW | 2 |
| Yang, JH | 2 |
| Kim, SW | 1 |
| Um, JM | 1 |
| Yang, Y | 1 |
| Zhao, XF | 1 |
| Li, HZ | 1 |
| Wang, W | 1 |
| Zhang, Y | 1 |
| Xiao, H | 1 |
| Zhang, X | 1 |
| Song, YS | 1 |
| Low, BY | 1 |
| Liong, ML | 1 |
| Yuen, KH | 1 |
| Chee, C | 1 |
| Leong, WS | 1 |
| Chong, WL | 1 |
| Khan, NA | 1 |
| Cheah, PY | 1 |
| Liong, KK | 1 |
| Theune, C | 1 |
| Frankel, G | 1 |
| Drabick, JJ | 1 |
| Gambel, JM | 1 |
| Mackey, JF | 1 |
| Zelefsky, MJ | 1 |
| Ginor, RX | 1 |
| Fuks, Z | 1 |
| Leibel, SA | 1 |
| Lee, TH | 1 |
| Serment, G | 1 |
| Rossi, D | 1 |
| Reitz, C | 1 |
| Boumendil, O | 1 |
| Suzuki, Y | 1 |
| Katoh, T | 1 |
| Isurugi, K | 1 |
| Obara, W | 1 |
| Omori, S | 1 |
| Goto, Y | 1 |
| Fujioka, T | 1 |
| Numasato, S | 1 |
| Boyle, P | 1 |
| Robertson, C | 1 |
| Manski, R | 1 |
| Padley, RJ | 1 |
| Roehrborn, CG | 1 |
| Park, YC | 1 |
| Nishioka, T | 1 |
| Arai, Y | 1 |
| Tomoyoshi, T | 1 |
| Kurita, T | 1 |
| Hayashida, H | 1 |
| Nagai, N | 1 |
| Inoue, H | 1 |
| Kataoka, K | 1 |
| Kitagawa, Y | 1 |
1 review available for terazosin and Urination Disorders
| Article | Year |
|---|---|
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Bayes Theorem; Humans; Male; Middle Aged; Prazosin; Prostatic Hy | 2001 |
10 trials available for terazosin and Urination Disorders
| Article | Year |
|---|---|
Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Chi-Square Distribution; Double-Blind Method; Flank Pain; H | 2011 |
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Biopsy; Brachytherapy; Doxazosin; Follow-Up Studies; H | 2002 |
Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Human | 2003 |
Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Hypertension; Male; Prazosin; Prostatic | 2003 |
Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cresols; Drug Therapy, Combination; Humans | 2007 |
Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Double-Blind Method; Female; Humans; Middle Aged; Prazosi | 2008 |
Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Dizziness; Double-Blind Method; Female; Headache; Humans; Middle | 1995 |
[Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination].
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Humans; Male; Practice Patterns, Physicians'; P | 2000 |
[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prazos | 2001 |
[A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M | 1992 |
12 other studies available for terazosin and Urination Disorders
| Article | Year |
|---|---|
Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy.
Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Child, Preschool; Female; Humans; Male; Prazosin; S | 2010 |
Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction.
Topics: Administration, Intravesical; Adrenergic alpha-Antagonists; Animals; Female; Infusions, Intravenous; | 2003 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietar | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Dr | 2004 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; | 2004 |
alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Pra | 2006 |
Significance of nocturnal hesitancy in treatment of men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Polyuria; Prazosin; Prospective Studies; Prostatic Hyper | 2006 |
Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Pra | 2007 |
Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Female; Humans; Prazosin; Randomized Controlled T | 1996 |
Prostatodynia in United Nations peacekeeping forces in Haiti.
Topics: Abscess; Adrenergic alpha-Antagonists; Adult; Age Factors; Anti-Bacterial Agents; Chronic Disease; C | 1997 |
Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Huma | 1999 |
By the way, doctor... I'm 78 and have more and more difficulty urinating. I get up three times a night - sometimes more - to go to the bathroom and it takes me a while to start urinating and even longer to stop. I know that this is probably a prostate pro
Topics: Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulf | 1999 |